Microfluidics (MFLU.OB) is a leader in advanced nano-material processing for a variety of industriesturn-around play with value characteristics. And it's cheap! ($0.99) Raygent Associates and The Rayno Report will be following up with a report on the company's technology after its earnings report in a couple weeks, but given the company's decent fundamentals and low price there is the potential for a strong move up. The company sells high-pressure microfluidic processors that are used to create materials on the micro-and nano-scale to achieve unique product characteristics and qualities. The technology achieves the following functionality:

• Particle size reduction
• Bottom-up nanoparticle creation
• Cell disruption
• Nanoencapsulation
• Nanoemulsions and dispersions

The applications for creating this microfluidic "features" is  development and manufacturing of a variety of products in diverse industries such as biotechnology, pharmaceutical, cosmetics and nutraceuticals. These products allow manufacturing to be scaled up in a uniform and repeatable way. For example, 17 of the top 20 pharmaceutical companies use microfluidizer processors and are of particular benefit to manufacturers of vaccines who need to create stable microemulsions of vaccines with their adjuvants. In the company's third quarter financial results released on November 3, 2009, it reported a net income of $450k on revenue of $4.5M with a backlog of $4.75M. Sales were strong from vaccine developers and manufacturers.The balance Sheet as of September 30 showed $1.7M in Cash with long-term convertible debt of $4.7M. Stockholder equity was $1.15M. One see this  company easily growing beyond it's current market cap of $10.5M. With 10.5 million shares outstanding that gives you a share price of $1. Assuming revenues of $18M for 2010 the price/sales ratio would be 0.583.